[68Ga]HNI01

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 41807884. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 41807884: '[68Ga]-labeled nanobody targeting CEA, namely [68Ga]Ga-HNI01'. | Stage 30 (2026-09-18): Modality was 'Therapy' -- a bucket value given to every agent found by the therapy-oriented bulk search (stages 21-22), not a source statement. Corrected to PET: Ga-68 is a positron emitter used only for PET imaging. Linked articles: PMID 41807884. Stage set/updated at stage 39 from PMID 41807884: 'only [68Ga]Ga-HNI01 and [68Ga]Ga-FAPI-04 have advanced to preliminary clinical evaluation phases'.